Apellis Pharmaceuticals, Inc. (APLS) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 8, 2022 4:05 PM EDTReceived U.S. FDA filing acceptance of NDA with Priority Review designation for intravitreal pegcetacoplan for treatment of geographic atrophy; PDUFA target action date of November 26, 2022Achieved $15.7 million in Q2 2022 EMPAVELI® (pegcetacoplan) U.S. net product revenuesDosed first patient in Phase 3 VALIANT study in IC-MPGN and C3GCash and investments of $852.8 million as of June 30, 2022; expected cash runway into Q1 2024Conference call scheduled today at 4:30 p.m. ET
WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) --... More
